NEWBURYPORT, Mass., Dec. 21, 2020 – Seqens CDMO North America (formerly known as PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs), and other specialty chemical products, issued its annual list of trends that will affect the emerging pharmaceutical and generic drug sectors, as well as Contract Development and Manufacturing Organizations (CDMOs), in 2021.
“While there’s good news about vaccines that will save lives and bring back a sense of normalcy, COVID-19 will continue to impact the life sciences sector. We expect supply chain and logistics to get a lot of coverage as the industry continues to ramp up to meet the unprecedented need to vaccinate the global population,” said Ed Price, founder, Seqens CDMO NA. “Companies and regulators need to make long-term systemic changes to ensure the U.S. and the world can be better positioned to handle potential disruption from a future pandemic. This will include finding new ways to protect supply chains and streamline processes to more easily work with regulators and get faster approvals while ensuring patient safety.”
Below are six trends that Seqens CDMO NA expects to impact the industry next year:
Seqens CDMO North America (formerly PCI Synthesis) is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass., a division of Seqens CDMO, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia.
Seqens CDMO North America is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. Seqens CDMO North America provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about Seqens CDMO North America, its proprietary NCE development activities and process R&D capabilities please visit www.seqens.com.